High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol.

CONCLUSIONS: Epo has robust neuroprotective effects in preclinical studies, and phase I/II trials suggest that multiple high doses of Epo may provide neuroprotection against brain injury in term infants. The High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial will evaluate whether high-dose Epo reduces the combined outcome of death or neurodevelopmental disability when given in conjunction with hypothermia to newborns with moderate/severe HIE. PMID: 29514165 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29514165?dopt=Abstract

Source: Neonatology - March 7, 2018 Category: Perinatology & Neonatology Authors: Juul SE, Comstock BA, Heagerty PJ, Mayock DE, Goodman AM, Hauge S, Gonzalez F, Wu YW Tags: Neonatology Source Type: research